This is a working overview of glucagon receptor, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-05-31 and is reviewed periodically as new material appears.
Peptides in this class degrade mainly through hydrolysis, oxidation, and aggregation. The lipid modification improves plasma residence time but can also promote self-association in aqueous solution at higher concentrations. Oxidation of methionine and deamidation of asparagine residues are common chemical liabilities that accumulate during storage. Stability studies therefore track purity loss, aggregate formation, and changes in receptor-binding potency over time under defined temperature and humidity conditions.
Solid peptide is generally held as a lyophilised powder at low temperature to slow degradation, with desiccant to limit moisture uptake. Reconstituted solutions are less stable and are usually kept refrigerated and protected from light for short periods. Repeated freeze-thaw cycles are avoided because they encourage aggregation. Laboratory handling includes work in a fume hood or laminar flow cabinet to limit inhalation and contamination. Weighing and transfer steps are performed with antistatic tools to reduce static-driven loss of fine powder.
Characterising a peptide of this size relies on a combination of chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the intact molecule from related impurities, while electrospray mass spectrometry confirms molecular mass and detects truncation or oxidation products. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates modified residues. Because the molecule carries a lipid chain, assays must also distinguish the correctly conjugated product from incompletely acylated species.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
| Property | Value | Notes |
|---|---|---|
| Storage temperature (solid) | -20 °C or below | Freezer storage with desiccant |
| Solubility | Soluble in water and aqueous buffer | Careful dissolution needed at higher concentrations |
| Appearance | White to off-white lyophilised powder | Visual inspection for discolouration |
| Primary analytical method | Reversed-phase HPLC with UV detection | Paired with mass spectrometry for identity |
| Common synonyms | Triple-agonist peptide; GLP-1/GIP/glucagon agonist | Naming varies across the literature |
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
The three-receptor design places retatrutide in a distinct category relative to older incretin-based therapies. Single agonists target one receptor, and dual agonists target two. Adding a third target broadens the pharmacological footprint and introduces new trade-offs among efficacy, tolerability, and glucose control. How these trade-offs resolve in large trials is a central focus of current research.
Retatrutide is an investigational peptide studied for obesity and type 2 diabetes. It is a single synthetic molecule designed to activate three metabolic receptors simultaneously. The compound belongs to the incretin mimetic family, a group of peptides that imitate gut hormones involved in appetite and glucose control. Its research code is LY3437943, and it remains under clinical study rather than cleared for routine medical use.
Acting as a triple agonist, the molecule binds the GLP-1, GIP, and glucagon receptors. GLP-1 activity slows gastric emptying and dampens appetite, while GIP signaling contributes to insulin sensitivity and fat metabolism. Glucagon receptor engagement raises energy expenditure and encourages fat breakdown, although it can also elevate blood glucose. Combining three pathways is intended to yield larger weight reduction than single or dual agonists, and researchers continue to examine how the balance among them shapes tolerability.
In 1941 Admiral Isoroku Yamamoto ordered the assembly of the Imperial Japanese Navy strike-force for the Hawaii Operation attack on Pearl Harbor in Tankan or Hitokappu Bay, Iturup Island, South Kurils. The territory was chosen for its sparse population, lack of foreigners, and constant fog-coverage. The Admiral ordered the move to Hawaii on the morning of 26 November. On 10 July 1943 the first bombardment against the Japanese bases in Shumshu and Paramushir by American forces occurred. From Alexai airfield 8 North American B-25 Mitchells from the 77th Bombardment Squadron took off, led by Capt James L. Hudelson. This mission principally struck Paramushir. Another mission was flown during 11 September 1943 when the Eleventh Air Force dispatched eight Consolidated B-24 Liberators and 12 B-25s. Facing reinforced Japanese defenses, 74 crew members in three B-24s and seven B-25 failed to return. 22 men were killed in action, one taken prisoner and 51 interned in Kamchatka. The Eleventh Air Force implemented other bombing missions against the northern Kurils, including a strike by six B-24s from the 404th Bombardment Squadron and 16 P-38s from the 54th Fighter Squadron on 5 February 1944. Japanese sources report that the Matsuwa military installations were subject to American air-strikes between 1943 and 1944. The Americans' strategic feint called "Operation Wedlock" diverted Japanese attention north and misled them about the U.S. strategy in the Pacific. The plan included air strikes by the USAAF and U.S. Navy bombers which included U.S.
A SNAP-19C RTG was lost near the top of Nanda Devi mountain in India in 1965, when it was stored in a rock formation near the top of the mountain in the face of a snowstorm. It was intended to power a CIA remote automated intelligence station collecting telemetry from the Chinese rocket testing facility at Lop Nur. The seven capsules were probably carried down the mountain onto a glacier by a subsequent avalanche and have never been recovered. It is most likely that they melted through the glacier and were pulverized, whereupon the 238Pu–Zr alloy fuel oxidized soil particles that are moving in a plume under the glacier. As the glaciers from these peaks feed some of India's largest rivers, including the Ganges, there are concerns about massive radioactive contamination originating from these RTGs. Accounts from the operatives who attempted the installation recounted that the sherpas who aided their mission jockeyed to carry the capsules as they produced heat; referring to the capsules as Guru Rinpoche, the warmth offered some respite from the freezing winds, but some of the operatives thought the capsules were inadequately shielded and irradiated the men around them.
==== Addition of hydrogen sulfide and mercaptans ==== When reacting with the hydrogen sulfide, ethylene oxide forms 2-mercaptoethanol and thiodiglycol, and with alkylmercaptans it produces 2-alkyl mercaptoethanol:
In White Women, Race Matters: The Social Construction of Whiteness, Frankenberg argues race shapes both the lives of the oppressor (white people, according to Frankenberg) as well as the oppressed. Frankenberg examined ways in which Ashkenazi Jewish women experience a sense of cultural belonging, but do not consider their Jewish faith to be classified a formal "race". Gillian Freeman (1929–2019) novelist and screenwriter; best known for her screenplays for The Leather Boys, I Want What I Want (film) and Only Lovers Left Alive (novel) Hadley Freeman (born 15 May 1978) American British journalist based in London; writes for the Jewish Chronicle, The Guardian and Vogue; of Austro-Hungarian and Polish Jewish ancestry. Anna Freud CBE (3 December 1895 – 9 October 1982); psychoanalyst of Austrian–Jewish descent; born in Vienna; youngest child of Sigmund Freud and Martha Bernays and followed path of father and contributed to field of psychoanalysis; alongside Hermine Hug-Hellmuth and Melanie Klein, is considered founder of psychoanalytic child psychology. Stephen Fry (born 24 August 1957) is an English actor, broadcaster, comedian, director, narrator and writer. He has written novels, non fiction, scripts and autobiography.
In maggot debridement therapy, sterile, medical-grade larvae of the necrophagous fly Lucilia sericata are used to eliminate necrotic (dead) tissue from non-healing skin and soft-tissue wounds. This is important as dead tissue can facilitate bacterial growth, impede wound healing, and reduce the effectiveness of topical medications. Physicians may administer the fly larvae directly to skin and soft tissue wounds or indirectly within a sealed mesh bag. Larvae then debride the wound by digesting, liquefying and consuming the dead tissue. The US Food and Drug Administration (FDA) have cleared Lucilia sericata larvae for use as a "medical device" in the US to debride several types of wound including pressure ulcers, neuropathic foot ulcers, and nonhealing surgical wounds.
Sources: en.wikipedia.org
Carbetocin, sold under the brand names Pabal among others, is a medication used to prevent excessive bleeding after childbirth, particularly following Cesarean section. It appears to work as well as oxytocin. Due to it being less economical than other options, use is not recommended by NHS Scotland. It is given by injection into a vein or muscle. Side effects differ little from that of no treatment or placebo. Use is not recommended in people with epilepsy or eclampsia. Carbetocin is a manufactured long acting form of oxytocin. It works by activating the oxytocin receptor which causes the uterus to contract. Carbetocin was synthesized before 1971 at the Czechoslovak Institute of Organic Chemistry and Biochemistry and was first described by 1974. It was approved for medical use in Canada and the United Kingdom in 1997. It is on the World Health Organization's List of Essential Medicines. It is not available in the United States or Japan.
== History == LFTs derive from paper chromatography, which was developed in 1943 by Martin and Synge, and elaborated in 1944 by Consden, Gordon and Martin. There was an explosion of activity in this field after 1945. The ELISA technology was developed in 1971. A set of LFT patents, including the litigated US 6,485,982 described below, were filed by Armkel LLC starting in 1988. The first commercially available lateral flow device was Unipath's Clearblue One Step in 1988. This product combined Paired Monoclonal Antibody technology (patented in 1980 by Unipath's Prof. Philip Porter and colleagues including Paul Davis and Keith May) and the original Clearblue product launched in June 1985.
{\displaystyle {\begin{aligned}{\frac {\partial f(t,j)}{\partial t}}&=2k_{+}m(t)f(t,j-1)-2k_{+}m(t)f(t,j)\\&+2k_{\rm {off}}f(t,j+1)-2k_{\rm {off}}f(t,j)\\&+k_{-}\sum _{i=j+1}^{\infty }f(t,i)-k_{-}(j-1)f(t,j)\\&+k_{1}m(t)^{n_{1}}\delta _{j,n_{1}}+k_{2}m(t)^{n_{2}}M(t)\delta _{j,n_{2}}\\\\\end{aligned}}}
== Biological functions == (Z)-9-Tricosene is a sex pheromone produced by female house flies (Musca domestica) to attract males. In bees, it is one of the communication pheromones released during the waggle dance.
Sources: en.wikipedia.org
Mass spectrometry provides the most direct confirmation of molecular mass. Reversed-phase chromatography adds a retention-time signature that supports identity when compared against a reference standard. No single method is sufficient on its own.
Cool, dry conditions with desiccant are standard for the solid form. Long-term storage is usually at freezer temperatures, with short-term handling at refrigerator temperature. Vials are allowed to equilibrate before opening to prevent condensation.
Lipid conjugation increases hydrophobicity, which shifts chromatographic retention and can broaden peaks. It also creates additional related species when acylation is incomplete or the chain is oxidised. Methods are therefore developed to separate acylated and non-acylated forms explicitly.
It is a synthetic peptide triagonist that engages GIP, GLP-1, and glucagon receptors. Investigational compounds in this class are studied for metabolic conditions rather than for a single organ system.